Chronic Lung Disease as a Risk Factor for Long COVID in Patients Diagnosed With Coronavirus Disease 2019: A Retrospective Cohort Study.

ingentiumby ingentium

In Long Covid Literature.

Publication date: Aug 01, 2024

Patients with coronavirus disease 2019 (COVID-19) often experience persistent symptoms, known as postacute sequelae of COVID-19 or long COVID, after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Chronic lung disease (CLD) has been identified in small-scale studies as a potential risk factor for long COVID. This large-scale retrospective cohort study using the National COVID Cohort Collaborative data evaluated the link between CLD and long COVID over 6 months after acute SARS-CoV-2 infection. We included adults (aged ≥18 years) who tested positive for SARS-CoV-2 during any of 3 SARS-CoV-2 variant periods and used logistic regression to determine the association, considering a comprehensive list of potential confounding factors, including demographics, comorbidities, socioeconomic conditions, geographical influences, and medication. Of 1 206 021 patients, 1. 2% were diagnosed with long COVID. A significant association was found between preexisting CLD and long COVID (adjusted odds ratio [aOR], 1. 36). Preexisting obesity and depression were also associated with increased long COVID risk (aOR, 1. 32 for obesity and 1. 29 for depression) as well as demographic factors including female sex (aOR, 1. 09) and older age (aOR, 1. 79 for age group 40-65 [vs 18-39] years and 1. 56 for >65 [vs 18-39] years). CLD is associated with higher odds of developing long COVID within 6 months after acute SARS-CoV-2 infection. These data have implications for identifying high-risk patients and developing interventions for long COVID in patients with CLD.

Open Access PDF

Concepts Keywords
Coronavirus chronic lung disease
Covid long COVID
Obesity SARS-CoV-2 infection
Socioeconomic

Semantics

Type Source Name
disease MESH Long COVID
disease MESH Coronavirus Disease 2019
disease MESH sequelae
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH obesity
drug DRUGBANK Ranitidine
disease VO USA
disease MESH Infectious Diseases
disease MESH viral infection
disease MESH Retirement
drug DRUGBANK Coenzyme M
disease MESH life stress
drug DRUGBANK Tretamine
disease VO primary vaccination
disease MESH lung disease
disease MESH COPD
disease MESH asthma
pathway KEGG Asthma
disease IDO symptom
drug DRUGBANK Ademetionine
disease MESH sleep disordered breathing
disease IDO history
disease MESH substance abuse
disease VO vaccination
disease VO unvaccinated
disease MESH emergency
disease MESH cardiovascular diseases
disease MESH cognitive disorders
disease MESH tumors
disease MESH reinfection
disease MESH morbidities
disease MESH Death
disease VO population
disease MESH bronchiectasis
disease IDO immunodeficiency
disease MESH malnutrition
disease MESH psychosis
disease MESH dementia
disease VO URE
disease MESH hemiplegia
disease MESH paraplegia
disease MESH HIV infection
disease MESH hypertension
disease VO vaccinated
drug DRUGBANK Medical air
disease MESH cytokine storm
drug DRUGBANK Proline
disease MESH chronic conditions
disease VO protocol
disease IDO susceptibility
disease MESH lifestyle
disease MESH inflammation
disease MESH loneliness
disease MESH immunocompromised hosts
drug DRUGBANK Vorinostat

Original Article

(Visited 1 times, 1 visits today)